catalog number :
MBS741626
products type :
ELISA Kit
products full name :
Canine Mullerian Inhibiting Substance/Anti Mullerian Hormone ELISA Kit
products short name :
Mullerian Inhibiting Substance/Anti Mullerian Hormone
other names :
muellerian-inhibiting factor; Muellerian-inhibiting factor; muellerian-inhibiting factor; anti-Muellerian hormone; Mullerian inhibiting factor; Mullerian inhibiting substance; muellerian-inhibiting substance; anti-Mullerian hormone; Anti-Muellerian hormone; AMH; Muellerian-inhibiting substance; MIS
products gene name :
MIS/AMH
other gene names :
AMH; AMH; MIF; MIS; MIF; AMH; MIS
uniprot entry name :
MIS_HUMAN
storage stability :
Store all reagents at 2-8 degree C.
other info1 :
Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 0.1 ng/mL.
other info2 :
Intended Uses: This AMH ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Canine AMH. This ELISA kit for research use only, not for therapeutic or diagnostic applications!
products categories :
Signal Transduction
products description :
Principle of the Assay: AMH ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-AMH antibody and an AMH-HRP conjugate. The assay sample and buffer are incubated together with AMH-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the AMH concentration since AMH from samples and AMH-HRP conjugate compete for the anti-AMH antibody binding site. Since the number of sites is limited, as more sites are occupied by AMH from the sample, fewer sites are left to bind AMH-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The AMH concentration in each sample is interpolated from this standard curve.
ncbi acc num :
NP_000470.2
ncbi gb acc num :
NM_000479.3
ncbi mol weight :
59,195 Da
ncbi pathways :
ALK2 Signaling Events Pathway (137983); Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); Hippo Signaling Pathway (749777); Hippo Signaling Pathway (750388); TGF-beta Signaling Pathway (83064); TGF-beta Signaling Pathway (475); CAMP Signaling Pathway (1017634); CAMP Signaling Pathway (1019520)
ncbi summary :
Anti-Mullerian hormone is a member of the transforming growth factor-beta gene family which mediates male sexual differentiation. Anti-Mullerian hormone causes the regression of Mullerian ducts which would otherwise differentiate into the uterus and fallopian tubes. Some mutations in the anti-Mullerian hormone result in persistent Mullerian duct syndrome. [provided by RefSeq, Jul 2008]
uniprot summary :
AMH: This glycoprotein, produced by the Sertoli cells of the testis, causes regression of the Muellerian duct. It is also able to inhibit the growth of tumors derived from tissues of Muellerian duct origin. Defects in AMH are the cause of persistent Muellerian duct syndrome type 1 (PMDS1). PMDS1 is a form of male pseudohermaphroditism characterized by a failure of Muellerian duct regression in otherwise normal males. Belongs to the TGF-beta family. Protein type: Secreted, signal peptide; Secreted. Chromosomal Location of Human Ortholog: 19p13.3. Cellular Component: extracellular space; cytoplasm; extracellular region. Molecular Function: growth factor activity; hormone activity; transforming growth factor beta receptor binding; receptor binding. Biological Process: sex determination; response to drug; Mullerian duct regression; cell-cell signaling; preantral ovarian follicle growth; gonadal mesoderm development; sex differentiation; response to organic cyclic substance; urogenital system development; aging; activation of NF-kappaB transcription factor. Disease: Persistent Mullerian Duct Syndrome, Types I And Ii